Treatment with 89SrCl and Sodium Ibandronate for pain relief of multiple bone metastases
10.3760/cma.j.issn.0253-9780.2010.04.012
- VernacularTitle:89SrCl联合依班膦酸钠治疗多发性骨转移癌疼痛
- Author:
Zhan, GAO
;
Gui-hua, QIU
;
Rong-guang, GAO
- Publication Type:Journal Article
- Keywords:
Neoplasm metastasis;
Bone neoplasms;
Pain;
Brachytherapy;
Strontium radioisotopes;
Sodium Ibandronate
- From:Chinese Journal of Nuclear Medicine
2010;30(4):264-266
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the palliative effect on pain relief in patients with multiple bone metastases treated with 89SrCl2 together with Sodium Ibandronate,Sodium Ibandronate alone and 89SrCl2 alone. Methods Eighty-four patients with bone pain secondary to bone metastases were divided into three groups. Thirty patients were treated with combined 89SrCl2 and Sodium Ibandronate,26 with 89SrCl2 alone and 28 with Sodium Ibandronate alone. The x2 test was used in data analysis. Results The overall palliative pain relief rate in the combined treatment group was 96.6 % (29/30). For the groups using Sodium Ibandronate or 89SrCl2 only,the palliative rates were 71.4% (20/28) and 73.1% (19/26),respectively. There are statistically significant differences between the combined treatment group and the other 2 groups with single treatment modalities in the overall palliative pain relief rate (x2 = 7.497 ),in terms of improvement in (1) whole body Karnofsky performance status (KPS) score (80.0% (24/30) vs 50.0% (14/28)/53.8% (14/26),x2 =35.476) and (2) focal palliative rate (47.6% (50/105) vs 11.2% (11/98)/22.2% (20/90),x2 =6. 564,all P ＜ 0. 05 ). Conclusions Combined treatment with 89 SrCl2 and Sodium Ibandronate is more effective than single treatment modalities to relieve bone pain seccondary to multiple bone metastases.
